Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Medtronic
McKesson
Dow
Express Scripts

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for APD421

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for APD421?

APD421 is an investigational drug.

There have been 10 clinical trials for APD421. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2013.

The most common disease conditions in clinical trials are Postoperative Nausea and Vomiting, Vomiting, and Nausea. The leading clinical trial sponsors are Acacia Pharma Ltd and [disabled in preview].

There is one US patent protecting this investigational drug and eight international patents.

Recent Clinical Trials for APD421
TitleSponsorPhase
Study of APD421 With and Without OndansetronAcacia Pharma LtdPhase 1
Mass-balance Study of [14C]-APD421 in Healthy VolunteersAcacia Pharma LtdPhase 1
Study of APD421 as PONV Treatment (Prior Prophylaxis)Acacia Pharma LtdPhase 3

See all APD421 clinical trials

Clinical Trial Summary for APD421

Top disease conditions for APD421
Top clinical trial sponsors for APD421

See all APD421 clinical trials

US Patents for APD421

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
APD421   Start Trial METAP2 inhibitors and methods of treating obesity SynDevRx, Inc. (Cambridge, MA)   Start Trial
APD421   Start Trial Pyrimidinyl-diazospiro compounds Convergence Pharmaceuticals Limited (Maidenhead, GB)   Start Trial
APD421   Start Trial Organic compounds INTRA-CELLULAR THERAPIES, INC. (New York, NY)   Start Trial
APD421   Start Trial Drug device configured for wireless communication Pop Test Abuse Deterrent Technology, LLC (Cliffside Park, NJ)   Start Trial
APD421   Start Trial 1,2-substituted cyclopentanes as orexin receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka-Shi, Osaka, JP)   Start Trial
APD421   Start Trial Substituted pyridazines for the treatment of pain INHIBITAXIN LIMITED (Sandwich Kent, GB)   Start Trial
APD421   Start Trial Synthetic peptide amides and dimers thereof Cara Therapeutics, Inc. (Stamford, CT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for APD421

Drugname Country Document Number Estimated Expiration Related US Patent
APD421 Argentina 095828 2033-04-10   Start Trial
APD421 Australia 2014250983 2033-04-10   Start Trial
APD421 Brazil 112015025892 2033-04-10   Start Trial
APD421 Canada 2908993 2033-04-10   Start Trial
APD421 China 105431426 2033-04-10   Start Trial
APD421 Denmark 2984085 2033-04-10   Start Trial
APD421 Eurasian Patent Organization 201591943 2033-04-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts
Mallinckrodt
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.